SimpleSENSE is designed to provide a digital tool to assess continuous and synchronous clinical biomarker data and trends.
Nanowear, an artificial intelligence (AI)-based remote diagnostics platform built on FDA-cleared nanotechnology and machine learning, has formed a commercial distribution partnership with an aesthetic and reconstructive surgical device-manufacturer, to enhance and optimize post-surgical recovery for both patients and surgeons.
“With over 18 million annual procedures in the U.S. alone, we’re proud to deploy our remote diagnostics platform to patients recovering from aesthetic and reconstructive surgery while providing digital signatures to the surgical teams who care for these patients,” said Venk Varadan, co-founder and chief executive officer of Nanowear.
Gender-neutral and size-adjustable, Nanowear’s SimpleSENSE platform is designed to effectively replace the digital stethoscope, multi-channel electrocardiograph monitor, capnogram respiration machine, and blood pressure cuff by providing a diagnostic quality monitoring system that remotely captures and analyzes 100 million+ biomarker data points per patient per day, time synchronously assessing the heart, lungs, and upper vascular system. This multi-variant, all-in-one product is designed to enable a closed-loop AI neural network, accruing daily benefits to both the provider and patient. Nanowear completed a beta-rollout in late 2020 and early 2021 at three American-based plastic surgical sites, which utilize devices to perform minimally invasive aesthetic and reconstructive surgeries.
“Not only does SimpleSENSE enable our patients to avoid in-person follow-up visits where we assess day-to-day biomarkers around surgical recovery, but it also allows us to begin shaping digital signatures of the recovery process,” said plastic surgeon, Erez Dayan, MD, of Avance Plastic Surgery in Reno, Nev. “Other technologies in the space do not have 85 machine learning dimensions of repeatable, high fidelity biomarker data feeding a swiftly growing neural network as Nanowear does. The “how” of each individual patient’s recovery is compelling, not only from what we see following our specialty procedures, but likely for the pre-, peri-, and post-procedural world in general.”
With the increased need for telemedicine and remote diagnostic monitoring, SimpleSENSE is built to provide a digital tool to assess continuous and synchronous clinical biomarker data and trends in a way that has not been previously available, according to the company. This empowers clinicians to treat patient problems earlier and more effectively. The platform lets Nanowear commercially partner with a variety of specialty original equipment manufacturers requiring data-driven remote diagnostics as opposed to remaining in a vertical silo such as electrocardiogram monitoring or arrhythmia detection.
